Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy of Cardiovascular Disease Risk Prediction Tools in Patients with Rheumatoid Arthritis

  • By

  • Tate M. Johnson

  • Halie Frideres

  • Punyasha Roul

  • Joshua F. Baker

  • Brian C. Sauer

  • Grant W. Cannon

  • Isaac D. Smith

  • Gary A. Kunkel

  • Beth I. Wallace

  • Thomas R. Porter

  • Kaveh R. Bookani

  • Amarnath R. Annapureddy

  • Ted R. Mikuls

  • Bryant R. England

  • July 1, 2026

Share

Clinical Report: Efficacy of Cardiovascular Disease Risk Prediction Tools in Patients with Rheumatoid Arthritis

Overview

This study evaluates the performance of the AHA's PREVENT calculators in predicting cardiovascular disease (CVD) risk in patients with rheumatoid arthritis (RA) compared to matched controls and the Pooled Cohort Equations (PCE).

Background

Rheumatoid arthritis is associated with increased cardiovascular disease risk, which is often underestimated by general population risk calculators. The development of RA-specific risk calculators has been attempted, but none have demonstrated superior performance in external validation studies.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

  • Cardiovascular disease is the leading cause of death in patients with rheumatoid arthritis.
  • General population CVD risk calculators often underestimate risk in RA patients.
  • The AHA's PREVENT calculators incorporate factors like BMI and renal function.
  • Existing RA-specific risk calculators have not outperformed general population calculators in validation studies.
  • There is currently no data-driven strategy for CVD risk stratification in RA.

Clinical Implications

Healthcare professionals should be aware that traditional CVD risk calculators may not adequately assess risk in patients with rheumatoid arthritis.

Conclusion

Accurate cardiovascular risk assessment in rheumatoid arthritis remains a challenge.

Related Resources & Content

  1. Clinical Rheumatology, 2025 -- Validation of Cardiovascular Risk Assessment Tools in Psoriatic Disease: Insights from a UK Biobank Analysis
  2. Sentara, 2025 -- Cardiovascular Risk in Rheumatoid Arthritis: What Clinicians Need to Know
  3. Frontiers in Medicine, 2026 -- Development and validation of a risk stratification model for cardiovascular disease in patients with radiographic axial spondyloarthritis (r-axSpA): a retrospective study
  4. Clinical Rheumatology, 2024 -- Evaluation of Cardiovascular Disease Risk in Individuals with Rheumatoid Arthritis: A Scoping Review
  5. Guideline on the Management of Dyslipidemia - Professional Heart Daily | American Heart Association, 2026
  6. Guideline on the Management of Dyslipidemia - Professional Heart Daily | American Heart Association
  7. https://academic.oup.com/rheumatology/article/64/10/5245/8145577

Original Source(s)

Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis

  • by Tate M. Johnson, Halie Frideres, Punyasha Roul, Joshua F. Baker, Brian C. Sauer, Grant W. Cannon, Isaac D. Smith, Gary A. Kunkel, Beth I. Wallace, Thomas R. Porter, Kaveh R. Bookani, Amarnath R. Annapureddy, Ted R. Mikuls, Bryant R. England

  • July 1, 2026

Related Content

Emergency diagnosis may flag poor outcomes beyond cancer

Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality.

A distinct gastrointestinal symptom profile characterizes clinically relevant fatigue in systemic sclerosis

Menopause may be underdocumented in EHRs

Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.